Brett Monia, Ionis Pharmaceuticals CEO
Ionis presents pivotal rare disease data, builds toward first solo launch: #ACC24
As Ionis gears up to launch its first wholly-owned medicine, researchers fleshed out its Phase 3 success in a rare genetic disease Sunday morning. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
